Period mismatch overshadows HY25 turn to positive EBITDAF and FCF

That produces a -39.7% revenue change to NZ$41.5m and a 70.6% narrowing of the pre-tax loss to -NZ$4.6m, but neither is like-for-like. The release's own commentary cites HY24 revenue of NZ$36.3m and total income up 18% to NZ$42.7m on a 1H-vs-1H basis, which means the underlying read is modest growth rather than decline.

On a half-year footing, EBITDAF turned positive at NZ$1.0m from a NZ$0.8m HY24 loss, free cash flow was NZ$1.3m, the NPAT loss narrowed to -NZ$5.1m from HY24's -NZ$7.2m, and cash rose 55% to NZ$22.0m from NZ$14.1m at the FY24 close. Reported capex was NZ$2.8m for the half against NZ$11.4m across the full FY24.

The -39.7% revenue change and Annolyse's historical baselines compare a half-year against full years, so the supplied "below normal range" classification (4-period mean +108.2%) is not informative for this release. The cleaner read is HY25 versus HY24: revenue NZ$41.5m versus NZ$36.3m and total income +18%.

The underlying turn to positive cash generation is the substantive finding. EBITDAF moved from a NZ$0.8m loss to a NZ$1.0m profit, free cash flow was NZ$1.3m, and operating cash flow was NZ$4.7m. Pre-lease free cash flow at NZ$1.3m sits at the upper edge of the supplied 4-period range (mean -NZ$15.6m, max NZ$3.0m), which means this is the strongest cash outturn in the supplied window.

The balance sheet strengthened despite the optical revenue contraction. Cash rose to NZ$22.0m, total equity stands at NZ$112.5m, and no borrowings are disclosed. This matters because operating losses persist at the NPAT level (-NZ$5.1m), so funding capacity for continued investment is being preserved rather than drawn down.

The supplied 2H shape calculation, which shows HY25 as 86.3% of "FY25" revenue, is an artefact of the period mislabeling and should not be read as second-half weakness.

With underlying 1H growth tracking in the 14-18% area depending on whether revenue or total income is used, the relevant second-half question is whether the EBITDAF and FCF inflection holds at scale as fixed-cost leverage works in management's favour. Without the unstated guidance numbers, the precision of any FY25 forward read here is limited.

Capex fell to NZ$2.8m for the half from NZ$11.4m across the full FY24, which mechanically supports free cash flow; the question is whether that reflects a sustainable lower run-rate or deferred investment that will reappear later. Debtor days at 28.7 sit at the lower edge of Annolyse's historical range (mean 58.8 days, range 18-92.8), pointing to collection efficiency rather than a working-capital release flattering operating cash flow.

The analytical pass flags cash conversion as deteriorated (OCF NZ$4.7m versus NZ$5.9m), but that comparison is again half-year against full year and is therefore not a meaningful conversion read. Tax remains noisy, with an effective rate of -10.6% on a pre-tax loss versus -1.2% in the prior comparable, but the absolute amounts are small enough that this matters less than the cash and operating turn.

This briefing cannot assess like-for-like operating performance with confidence, because the supplied prior-period comparison is not on a half-year basis and detailed HY24 financials beyond commentary excerpts are not in the extraction.